Gini Fleming to Cytotoxicity, Immunologic
This is a "connection" page, showing publications Gini Fleming has written about Cytotoxicity, Immunologic.
Connection Strength
0.120
-
A phase II trial of trastuzumab in combination with low-dose interleukin-2 (IL-2) in patients (PTS) with metastatic breast cancer (MBC) who have previously failed trastuzumab. Breast Cancer Res Treat. 2009 Sep; 117(1):83-9.
Score: 0.081
-
Induction of Neoantigen-Specific Cytotoxic T Cells and Construction of T-cell Receptor-Engineered T Cells for Ovarian Cancer. Clin Cancer Res. 2018 11 01; 24(21):5357-5367.
Score: 0.039